FY2026 EPS Estimates for Krystal Biotech Lifted by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Krystal Biotech in a research note issued on Monday, November 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $7.02 per share for the year, up from their prior estimate of $6.47. HC Wainwright currently has a “Buy” rating and a $221.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.88 per share.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same period in the prior year, the firm posted ($0.67) earnings per share. The company’s revenue for the quarter was up 879.9% on a year-over-year basis.

Other equities analysts have also recently issued reports about the company. Citigroup boosted their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Evercore ISI boosted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. Chardan Capital raised their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $197.00.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $174.41 on Wednesday. The company has a market cap of $5.01 billion, a price-to-earnings ratio of 98.54 and a beta of 0.82. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34. The firm has a fifty day moving average price of $181.81 and a two-hundred day moving average price of $180.23.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Scout Investments Inc. bought a new stake in shares of Krystal Biotech in the 1st quarter worth approximately $8,976,000. Sei Investments Co. increased its position in Krystal Biotech by 128.3% during the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock valued at $6,005,000 after purchasing an additional 18,968 shares during the period. Janney Montgomery Scott LLC bought a new position in Krystal Biotech in the 1st quarter worth $3,175,000. Price T Rowe Associates Inc. MD raised its holdings in Krystal Biotech by 54.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after purchasing an additional 231,255 shares in the last quarter. Finally, Shaker Investments LLC OH purchased a new stake in shares of Krystal Biotech in the 3rd quarter worth about $532,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).